Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Dyskinesia, Drug-Induced

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Dyskinesia, Drug-Induced in 1 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lopez-Lopez, A1
Labandeira, CM1
Labandeira-Garcia, JL1
Muñoz, A1

Other Studies

1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Dyskinesia, Drug-Induced

ArticleYear
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    British journal of pharmacology, 2020, Volume: 177, Issue:24

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind

2020